Digest Network Come funziona
Network
/
Società
Be
Non verificato

BetaGlue Therapeutics SpA

Di cosa scriviamo

BiotecnologiaMedicina Salute Benessere

8 comunicati stampa

Guarda tutti i comunicati
15/12/2025
Biotecnologia
Medicina Salute Benessere
BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
15/12/2025
Biotecnologia
Medicina Salute Benessere
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
03/12/2025
Biotecnologia
Medicina Salute Benessere
BetaGlue Therapeutics étend son essai clinique en Italie après avoir obtenu l’autorisation du ministère de la Santé italien pour mener son étude clinique sur le cancer du pancréas localement avancé non résécable (uLA-PDAC)
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
02/12/2025
Biotecnologia
Medicina Salute Benessere
BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
13/11/2025
Biotecnologia
La MHRA approuve la demande d’essai clinique de BetaGlue Therapeutics pour YntraDose™ dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
12/11/2025
Biotecnologia
MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
22/09/2025
Biotecnologia
Medicina Salute Benessere
BetaGlue Therapeutics annonce la nomination d’Alexis Peyroles au poste de directeur général
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0
22/09/2025
Biotecnologia
Medicina Salute Benessere
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
Fonte
BetaGlue Therapeutics SpA
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0